Umfrage zur Nutzung unserer Internetseite
Sehr geehrte/r Besucher/in unseres Internetauftrittes,

wir, das Universitätsklinikum Halle (Saale), führen im Moment eine Umfrage über die Nutzung unserer Internetseite durch. Mit den Ergebnissen dieser völlig anonymen und freiwilligen Umfrage wollen wir unsere Seite für Sie attraktiver und besser nutzbar machen. Wir würden uns deshalb sehr über Ihre Teilnahme freuen. Das Beantworten der Fragen dauert auch nur wenige Minuten.

Unsere Datenschutzinformationen finden Sie unter Datenschutzerklärung
Ich möchte nicht teilnehmen

Publikationen Dr. Thomas Müller

Mueller T, Freystein J, Lucas H, and Schmoll HJ: Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model. Molecules 2019;24.

Werner S, Lutzkendorf J, Muller T, Muller LP, and Posern G: MRTF-A controls myofibroblastic differentiation of human multipotent stromal cells and their tumour-supporting function in xenograft models. Sci Rep 2019;9: 11725.

Schmitt F, Gosch LC, Dittmer A, Rothemund M, Mueller T, Schobert R, Biersack B, Volkamer A, and Hopfner M: Oxazole-Bridged Combretastatin A-4 Derivatives with Tethered Hydroxamic Acids: Structure(-)Activity Relations of New Inhibitors of HDAC and/or Tubulin Function. Int J Mol Sci 2019;20.

Steinemann G, Dittmer A, Schmidt J, Josuttis D, Fahling M, Biersack B, Beindorff N, Jolante Koziolek E, Schobert R, Brenner W, Muller T, Nitzsche B, and Hopfner M: Antitumor and antiangiogenic activity of the novel chimeric inhibitor animacroxam in testicular germ cell cancer. Mol Oncol 2019;13: 2679-96.

Schmitt F, Gold M, Rothemund M, Andronache I, Biersack B, Schobert R, and Mueller T: New naphthopyran analogues of LY290181 as potential tumor vascular-disrupting agents. Eur J Med Chem 2018;163: 160-8.


Mueller T, Hantsch C, Volkmer I, and Staege MS: Differentiation-Dependent Regulation of Human Endogenous Retrovirus K Sequences and Neighboring Genes in Germ Cell Tumor Cells. Front Microbiol 2018;9: 1253.

Weiss VM, Lucas H, Mueller T, Chytil P, Etrych T, Naolou T, Kressler J, and Mader K: Intended and Unintended Targeting of Polymeric Nanocarriers: The Case of Modified Poly(glycerol adipate) Nanoparticles. Macromol Biosci 2018;18. 

Mueller T, Pfankuchen DB, Wantoch von Rekowski K, Schlesinger M, Reipsch F, and Bendas G: The Impact of the Low Molecular Weight Heparin Tinzaparin on the Sensitization of Cisplatin-Resistant Ovarian Cancers-Preclinical In Vivo Evaluation in Xenograft Tumor Models. Molecules 2017;22: 728.

Schaffrath J, Schmoll HJ, Voigt W, Muller LP, Muller-Tidow C, and Mueller T: Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity. PLoS One 2017;12: e0178930.

Bahr I, Goritz V, Doberstein H, Hiller GG, Rosenstock P, Jahn J, Portner O, Berreis T, Mueller T, Spielmann J, and Kielstein H: Diet-Induced Obesity Is Associated with an Impaired NK Cell Function and an Increased Colon Cancer Incidence. J Nutr Metab 2017;2017: 4297025.

Schmitt F, Donnelly K, Muenzner JK, Rehm T, Novohradsky V, Brabec V, Kasparkova J, Albrecht M, Schobert R, and Mueller T: Effects of histidin-2-ylidene vs. imidazol-2-ylidene ligands on the anticancer and antivascular activity of complexes of ruthenium, iridium, platinum, and gold. J Inorg Biochem 2016;163: 221-8.

Heinrich AK, Lucas H, Schindler L, Chytil P, Etrych T, Mader K, and Mueller T: Improved Tumor-Specific Drug Accumulation by Polymer Therapeutics with pH-Sensitive Drug Release Overcomes Chemotherapy Resistance. Mol Cancer Ther 2016;15: 998-1007.

Studenovský M, Heinrich AK, Lucas H, Mueller T, Mader K, and Etrych T: Dual fluorescent N-(2-hydroxypropyl) methacrylamide-based conjugates for passive tumor targeting with reduction-sensitive drug release: Proof of the concept, tumor accumulation, and biodistribution. J Bioact Compat Polym 2016;31: 348-60.

Pola R, Heinrich AK, Mueller T, Kostka L, Mader K, Pechar M, and Etrych T: Passive Tumor Targeting of Polymer Therapeutics: In Vivo Imaging of Both the Polymer Carrier and the Enzymatically Cleavable Drug Model. Macromol Biosci 2016;16: 1577-82.

Mahal K, Biersack B, Schruefer S, Resch M, Ficner R, Schobert R, and Mueller T: Combretastatin A-4 derived 5-(1-methyl-4-phenyl-imidazol-5-yl)indoles with superior cytotoxic and anti-vascular effects on chemoresistant cancer cells and tumors. Eur J Med Chem 2016;118: 9-20.

Lomkova EA, Chytil P, Janouskova O, Mueller T, Lucas H, Filippov SK, Trhlikova O, Aleshunin PA, Skorik YA, Ulbrich K, and Etrych T: Biodegradable Micellar HPMA-Based Polymer-Drug Conjugates with Betulinic Acid for Passive Tumor Targeting. Biomacromolecules 2016;17: 3493-507.

Etrych T, Lucas H, Janouskova O, Chytil P, Mueller T, and Mader K: Fluorescence optical imaging in anticancer drug delivery. J Control Release 2016;226: 168-81.

Widder M, Lutzkendorf J, Caysa H, Unverzagt S, Wickenhauser C, Benndorf RA, Schmoll HJ, Muller-Tidow C, Muller T, and Muller LP: Multipotent mesenchymal stromal cells promote tumor growth in distinct colorectal cancer cells by a beta1-integrin-dependent mechanism. Int J Cancer 2016;138: 964-75.

Liebscher G, Vanchangiri K, Mueller T, Feige K, Cavalleri JV, and Paschke R: In vitro anticancer activity of Betulinic acid and derivatives thereof on equine melanoma cell lines from grey horses and invivo safety assessment of the compound NVX-207 in two horses. Chem Biol Interact 2016;246: 20-9.

Mahal K, Biersack B, Caysa H, Schobert R, and Mueller T: Combretastatin A-4 derived imidazoles show cytotoxic, antivascular, and antimetastatic effects based on cytoskeletal reorganisation. Invest New Drugs 2015;33: 541-54.

Kurze C, Le Conte Y, Dussaubat C, Erler S, Kryger P, Lewkowski O, Muller T, Widder M, and Moritz RF: Nosema Tolerant Honeybees (Apis mellifera) Escape Parasitic Manipulation of Apoptosis. PLoS One 2015;10: e0140174.

Belete A, Metz H, Mueller T, and Maeder K: Benchtop MRI for pharmacokinetic evaluation of two aqueous-based nano-scaled formulations of oleic acid stabilized magnetite nanocrystals. Drug Dev Ind Pharm 2015;41: 406-14.

Mahal K, Resch M, Ficner R, Schobert R, Biersack B, and Mueller T: Effects of the tumor-vasculature-disrupting agent verubulin and two heteroaryl analogues on cancer cells, endothelial cells, and blood vessels. ChemMedChem 2014;9: 847-54.

Rizzello CG, Mueller T, Coda R, Reipsch F, Nionelli L, Curiel JA, and Gobbetti M: Synthesis of 2-methoxy benzoquinone and 2,6-dimethoxybenzoquinone by selected lactic acid bacteria during sourdough fermentation of wheat germ. Microb Cell Fact 2013;12: 105.

Hoffmann S, Caysa H, Kuntsche J, Kreideweiss P, Leimert A, Mueller T, and Mader K: Carbohydrate plasma expanders for passive tumor targeting: in vitro and in vivo studies. Carbohydr Polym 2013;95: 404-13.

Gutekunst M, Mueller T, Weilbacher A, Dengler MA, Bedke J, Kruck S, Oren M, Aulitzky WE, and van der Kuip H: Cisplatin hypersensitivity of testicular germ cell tumors is determined by high constitutive Noxa levels mediated by Oct-4. Cancer Res 2013;73: 1460-9.

Chytil P, Hoffmann S, Schindler L, Kostka L, Ulbrich K, Caysa H, Mueller T, Mader K, and Etrych T: Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release II: impact of release rate on biodistribution. J Control Release 2013;172: 504-12.

Schadlich A, Hoffmann S, Mueller T, Caysa H, Rose C, Gopferich A, Li J, Kuntsche J, and Mader K: Accumulation of nanocarriers in the ovary: a neglected toxicity risk? J Control Release 2012;160: 105-12.

Kaps L, Biersack B, Muller-Bunz H, Mahal K, Munzner J, Tacke M, Mueller T, and Schobert R: Gold(I)-NHC complexes of antitumoral diarylimidazoles: structures, cellular uptake routes and anticancer activities. J Inorg Biochem 2012;106: 52-8.

Kaluderovic GN, Dietrich A, Kommera H, Kuntsche J, Mader K, Mueller T, and Paschke R: Liposomes as vehicles for water insoluble platinum-based potential drug: 2-(4-(tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum( II). Eur J Med Chem 2012;54: 567-72.

Hoffmann S, Vystrcilova L, Ulbrich K, Etrych T, Caysa H, Mueller T, and Mader K: Dual fluorescent HPMA copolymers for passive tumor targeting with pH-sensitive drug release: synthesis and characterization of distribution and tumor accumulation in mice by noninvasive multispectral optical imaging. Biomacromolecules 2012;13: 652-63.

Caysa H, Hoffmann S, Luetzkendorf J, Mueller LP, Unverzagt S, Mader K, and Mueller T: Monitoring of xenograft tumor growth and response to chemotherapy by non-invasive in vivo multispectral fluorescence imaging. PLoS One 2012;7: e47927.

Schobert R, Seibt S, Mahal K, Ahmad A, Biersack B, Effenberger-Neidnicht K, Padhye S, Sarkar FH, and Mueller T: Cancer selective metallocenedicarboxylates of the fungal cytotoxin illudin M. J Med Chem 2011;54: 6177-82.

Schadlich A, Rose C, Kuntsche J, Caysa H, Mueller T, Gopferich A, and Mader K: How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 2011;28: 1995-2007.

Schadlich A, Caysa H, Mueller T, Tenambergen F, Rose C, Gopferich A, Kuntsche J, and Mader K: Tumor accumulation of NIR fluorescent PEG-PLA nanoparticles: impact of particle size and human xenograft tumor model. ACS Nano 2011;5: 8710-20.

Mueller T, and Voigt W: Fermented wheat germ extract--nutritional supplement or anticancer drug? Nutr J 2011;10: 89.

Mueller T, Jordan K, and Voigt W: Promising cytotoxic activity profile of fermented wheat germ extract (Avemar(R)) in human cancer cell lines. J Exp Clin Cancer Res 2011;30: 42.

Mueller LP, Luetzkendorf J, Widder M, Nerger K, Caysa H, and Mueller T: TRAIL-transduced multipotent mesenchymal stromal cells (TRAIL-MSC) overcome TRAIL resistance in selected CRC cell lines in vitro and in vivo. Cancer Gene Ther 2011;18: 229-39.

Caysa H, Metz H, Mader K, and Mueller T: Application of Benchtop-magnetic resonance imaging in a nude mouse tumor model. J Exp Clin Cancer Res 2011;30: 69.

Biersack B, Dietrich A, Zoldakova M, Kalinowski B, Paschke R, Schobert R, and Mueller T: Lipophilic Pt(II) complexes with selective efficacy against cisplatin-resistant testicular cancer cells. J Inorg Biochem 2011;105: 1630-7.

Besheer A, Caysa H, Metz H, Mueller T, Kressler J, and Mader K: Benchtop-MRI for in vivo imaging using a macromolecular contrast agent based on hydroxyethyl starch (HES). Int J Pharm 2011;417: 196-203.

Schobert R, Biersack B, Dietrich A, Effenberger K, Knauer S, and Mueller T: 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -N-methylimidazoles that are cytotoxic against combretastatin A resistant tumor cells and vascular disrupting in a cisplatin resistant germ cell tumor model. J Med Chem 2010;53: 6595-602.

Mueller T, Mueller LP, Holzhausen HJ, Witthuhn R, Albers P, and Schmoll HJ: Histological evidence for the existence of germ cell tumor cells showing embryonal carcinoma morphology but lacking OCT4 expression and cisplatin sensitivity. Histochem Cell Biol 2010;134: 197-204.

Luetzkendorf J, Mueller LP, Mueller T, Caysa H, Nerger K, and Schmoll HJ: Growth inhibition of colorectal carcinoma by lentiviral TRAIL-transgenic human mesenchymal stem cells requires their substantial intratumoral presence. J Cell Mol Med 2010;14: 2292-304.

Kommera H, Kaluderovic GN, Dittrich S, Kalbitz J, Drager B, Mueller T, and Paschke R: Carbamate derivatives of betulinic acid and betulin with selective cytotoxic activity. Bioorg Med Chem Lett 2010;20: 3409-12.

Eisenmann S, Voigt W, Muller T, and Dempke W: Sequential X-irradiation induced acquired resistance to oxaliplatin but increased sensitivity to cisplatin in two human teratoma cell lines in vitro. Anticancer Res 2010;30: 4471-6.

Schobert R, Biersack B, Dietrich A, Knauer S, Zoldakova M, Fruehauf A, and Mueller T: Pt(II) complexes of a combretastatin A-4 analogous chalcone: effects of conjugation on cytotoxicity, tumor specificity, and long-term tumor growth suppression. J Med Chem 2009;52: 241-6.

Mueller T, Luetzkendorf J, Nerger K, Schmoll HJ, and Mueller LP: Analysis of OCT4 expression in an extended panel of human tumor cell lines from multiple entities and in human mesenchymal stem cells. Cell Mol Life Sci 2009;66: 495-503.

Dansranjavin T, Krehl S, Mueller T, Mueller LP, Schmoll HJ, and Dammann RH: The role of promoter CpG methylation in the epigenetic control of stem cell related genes during differentiation. Cell Cycle 2009;8: 916-24.

Kelly ME, Dietrich A, Gomez-Ruiz S, Kalinowski B, Kaluderović GN, Müller T, Paschke R, Schmidt J, Steinborn D, Wagner C, and Schmidt H: Platinum(IV) metallacrown ethers: Synthesis, structures, host properties and anticancer evaluation. Organometallics 2008;27: 4917-27.

Kaluderović GN, Schmidt H, Schwieger S, Wagner C, Paschke R, Dietrich A, Mueller T, and Steinborn D: Platinum(IV) complexes with ethylenediamine-N,N '-diacetate diester (R(2)edda) ligands: Synthesis, characterization and in vitro antitumoral activity. Inorganica Chimica Acta 2008;361: 1395-404.

Dietrich A, Mueller T, Paschke R, Kalinowski B, Behlendorf T, Reipsch F, Fruehauf A, Schmoll HJ, Kloft C, and Voigt W: 2-(4-(Tetrahydro-2H-pyran-2-yloxy)-undecyl)-propane-1,3-diamminedichloroplatinum( II): a novel platinum compound that overcomes cisplatin resistance and induces apoptosis by mechanisms different from that of cisplatin. J Med Chem 2008;51: 5413-22.

Schobert R, Biersack B, Dietrich A, Grotemeier A, Müller T, Kalinowski B, Knauer S, Voigt W, and Paschke R: Monoterpenes as drug shuttles: cytotoxic (6-aminomethylnicotinate)dichloridoplatinum(II) complexes with potential to overcome cisplatin resistance. J Med Chem 2007;50: 1288-93.

Kaluderović GN, Schmidt H, Paschke R, Kalinowski B, Dietrich A, Mueller T, and Steinborn D: Platinum(II) complexes with l-methionylglycine and l-methionyl-l-leucine ligands: synthesis, characterization and in vitro antitumoral activity. J Inorg Biochem 2007;101: 543-9.

Mueller T, Mueller LP, Luetzkendorf J, Voigt W, Simon H, and Schmoll HJ: Loss of Oct-3/4 expression in embryonal carcinoma cells is associated with induction of cisplatin resistance. Tumour Biol 2006;27: 71-83.

Mueller LP, Luetzkendorf J, Mueller T, Reichelt K, Simon H, and Schmoll HJ: Presence of mesenchymal stem cells in human bone marrow after exposure to chemotherapy: evidence of resistance to apoptosis induction. Stem Cells 2006;24: 2753-65.

Voigt W, Pickan V, Pfeiffer C, Mueller T, Simon H, and Arnold D: Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use. Onkologie 2005;28: 482-8.

Voigt W, Kegel T, Weiss M, Mueller T, Simon H, and Schmoll HJ: Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol 2005;131: 585-90.

Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, and Dempke W: Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Anticancer Res 2005;25: 1147-55.

Paschke R, Paetz C, Mueller T, Schmoll HJ, Mueller H, Sorkau E, and Sinn E: Biomolecules linked to transition metal complexes--new chances for chemotherapy. Curr Med Chem 2003;10: 2033-44.

Paschke R, Kalbitz J, Paetz C, Luckner M, Mueller T, Schmoll HJ, Mueller H, Sorkau E, and Sinn E: Cholic acid-carboplatin compounds (CarboChAPt) as models for specific drug delivery: synthesis of novel carboplatin analogous derivatives and comparison of the cytotoxic properties with corresponding cisplatin compounds. J Inorg Biochem 2003;94: 335-42.

Mueller T, Voigt W, Simon H, Fruehauf A, Bulankin A, Grothey A, and Schmoll HJ: Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer. Cancer Res 2003;63: 513-21.

Voigt W, Bulankin A, Müller T, Schoeber C, Grothey A, Hoang-Vu C, and Schmoll HJ: Schedule-dependent antagonism of gemcitabine and cisplatin in human anaplastic thyroid cancer cell lines. Clin Cancer Res 2000;6: 2087-93.

Grothey A, Voigt W, Schöber C, Müller T, Dempke W, and Schmoll HJ: The role of insulin-like growth factor I and its receptor in cell growth, transformation, apoptosis, and chemoresistance in solid tumors. J Cancer Res Clin Oncol 1999;125: 166-73.



Dr. rer. nat. Thomas Müller

Klinik für Innere Medizin IV

-Hämatologie und Onkologie-

Landeszentrum für Zell- und Gentherapie

Universitätsklinikum Halle (Saale)

Ernst-Grube-Str. 40

06120 Halle

Tel 0345-5577211

Fax 0345-5577279

Email: thomas.mueller(at)